摘要
经典名方作为中医理论的载体、临床治病的主要工具,是中医药传承发展的突破口之一。目录制管理的经典名方中药复方制剂研发、上市经典名方产品的二次开发、源于经典名方的中药新药研发,是经典名方研发的三条路径。本文探讨了每条路径的研发方向与重点内容;并从设立专家委员会、健全中药标准供给体系、发展第三方检测平台、建设质量可溯源体系、完善注册与招标的角度,提出经典名方发展的政策建议。
As the carrier of Chinese medicine（CM） theory as well as the main tool for clinical treatment,classical prescription,is one of the breakthroughs in the development of Chinese medicine. The research and development（ RD） of directory managed CM compound preparations,the secondary development of marked classical prescription products,CM new drug RD originating from classical prescriptions are three main paths for the RD of classical prescriptions. This article mainly discusses the direction and key points for the research of each path. Finally,recommendations for the development of classical prescription are proposed from aspects as below： establishing specialists committee,improving standard supply system of Chinese medicine,improving third-party testing platforms,building quality traceable systems,and perfecting registration and bidding.
作者
杨洪军
黄璐琦
YANG Hong-jun;HUANG Lu-qi(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Belting 100700,China;National Resource Center for Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国现代中药》
CAS
2018年第7期775-779,共5页
Modern Chinese Medicine
基金
中央本级重大增减支项目(2060302)
关键词
经典名方
大品种培育
中药新药
简化注册
Classical prescription
big brand cultivation
new drug of Chinese medicine
simplified registration
